Cyclovirobuxine D ameliorates cardiomyocyte senescence in diabetic cardiomyopathy mice by enhancing mitochondrial function via sirtuin 3-ATP5O signal axis.

Jiang-Fei An, Hang Su, Xue-Ting Wang, Guang-Qiong Zhang, Chao-da Xiao, BarBu Wollenberga, Yong-Xin Chen, Hong Yang, Hong Luo, Long Yang, Ling-Yun Fu, Yi-Ni Xu, Ling Tao, Xiang-Chun Shen

The State Key Laboratory of Functions and Applications of Medicinal Plants, Guizhou Medical University, No.6 Ankang Avenue, Guian New District, Guiyang, 561113, Guizhou, China. · pubmed

Paper

Abstract

Diabetic cardiomyopathy (DCM) is a cardiovascular complication, with cardiomyocyte senescence being a key pathological process. Cyclovirobuxine D (CVB-D), the active compound in Buxus sinica (Rehd. et Wils.) var. parvifolia M. Cheng. CVB-D has potentially promising diabetes-related cardiomyocyte senescence-mitigating effects. Nevertheless, the impact of CVB-D on inhibiting cardiomyocyte senescence has not been widely investigated and molecular mechanisms remain ambiguous.

The following analysis is generated by AI and may contain errors. It is separate from the authors’ abstract and is not peer review.

Research summary

Cyclovirobuxine D enhances mitochondrial function and ameliorates cardiomyocyte senescence in diabetic cardiomyopathy mice. The study addresses a key pathological process related to aging by exploring a potential intervention that targets cellular senescence, which is a significant contributor to age-related diseases.

Author of this paper? Send a correction.